Qu Biologics Granted US Patent For Use Of E. Coli To Treat Crohn’s Disease

Qu Biologics Granted US Patent For Use Of E. Coli To Treat Crohn’s Disease
Qu BiologicsQu Biologics Inc., a biotechnology firm currently developing Site Specific Immunomodulators (SSIs) to restore regular immune function in a specific targeted diseased organ, recently announced that the United States Patent and Trademark Office issued a U.S. Patent to the company for the utilization of immunotherapies that are collected from components of E. coli with the purpose of treating Crohn's disease. The patent was issued on March 17, 2015 and it claims the usage of E. coli components such as SSIs to boost the immune response and provide treatment for Crohn's disease. This recent patent is based on Qu Biologics' patent portfolio that includes SSI treatment of multiple inflammatory disorders and cancers. Hal Gunn, who is the Qu Biologics' Chief Executive Officer said in a press release: "We are very pleased to have been granted this important U.S. patent that covers our novel Crohn's treatment in clinical use in our randomized, placebo-controlled clinical trial. Our SSIs aim to address the underlying immunological causes of many chronic inflammatory diseases, representing a novel treatment approach that restores the bod
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *